Difference between revisions of "WHIM syndrome"
Jump to navigation
Jump to search
| Line 15: | Line 15: | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:be34d7|Variant=1}}=== | ===Regimen {{#subobject:be34d7|Variant=1}}=== | ||
| − | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
| − | !style="width: | + | !style="width: 33%"|Study |
| − | !style="width: | + | !style="width: 33%"|Dates of enrollment |
| + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ McDermott et al. 2019] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ McDermott et al. 2019] | ||
| + | |NR | ||
|style="background-color:#ffffbe"|Pilot, fewer than 20 pts | |style="background-color:#ffffbe"|Pilot, fewer than 20 pts | ||
|- | |- | ||
Revision as of 12:03, 3 July 2024
| Section editor | |
|---|---|
 |
Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA |
WHIM: Warts, Hypogammaglobulinemia, Infections, Myelokathexis
1 regimens on this page
1 variants on this page
|
All lines of therapy
Plerixafor monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| McDermott et al. 2019 | NR | Pilot, fewer than 20 pts |
References
- Case series: McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. link to original article link to PMC article contains dosing details in manuscript PubMed